Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001104659-25-116119·Dianthus Therapeutics, Inc. /DE/
Schedule 13D ownership disclosure
DIANTHUS THERAPEUTICS INC COM
Common Stock, $0.001 par value · CUSIP: 252828108
Event date: 2025-11-21
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Fairmount Funds Management LLCReported CIK 0001802528
Shares: 2,139,635.00 · Class: 4.9%
- Fairmount Healthcare Fund II L.P.Reported CIK 0001769651
Shares: 2,139,635.00 · Class: 4.9%
- Peter Evan HarwinReported CIK 0001663607
Shares: 2,139,635.00 · Class: 4.9%
- Tomas KiselakReported CIK 0001830177
Shares: 2,139,635.00 · Class: 4.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-116119
- Form type
- SCHEDULE 13D/A
- Filer
- Dianthus Therapeutics, Inc. /DE/
- CIK
- CIK 1690585
- Filed
- Nov 25, 2025
- Reporting period
- Nov 21, 2025
- Description
- Schedule 13D beneficial ownership